Survival analysis and treatment strategies for limb liposarcoma patients with metastasis at presentation

Abstract

Limited data exist on patients with limb liposarcoma (LLS) with metastasis at presentation Moreover, the potential prognostic factors of this patient population are poorly documented because of its rarity. Therefore, we conducted this study to evaluate the clinicopathologic characteristics and prognostic factors for patients with metastatic LLS. All patients with LLS with metastasis at presentation from 1975 to 2016 were identified by using the Surveillance, Epidemiology, and End Results (SEER) database. The following clinical data were derived from this clinical database: age, sex, histologic grade, subtype, size of tumor, surgery, radiotherapy, chemotherapy, vital status, cause of death, and survival duration. The Kaplan-Meier method was performed to calculate median survival time and draw survivorship curves. Cox-proportional hazards regression model was used to reveal the statistical independence between various variables. The present study collected 184 cases from SEER database for survival analysis. Mean age was 57.8 years with 63.6% (n = 117) men. The 3-year overall survival (OS) and cancer-specific survival (CSS) rates of this population were 27.8% and 30.1%, respectively. Univariate analysis revealed that age, tumor grade, and surgery were significantly correlated with survival. Sex and tumor size did not reach significant predictor status of survival. Multivariate analysis revealed that age at diagnosis <60, low tumor grade, and local surgery were significantly correlated with improved OS and CSS. Patients with LLS with metastasis at diagnosis experienced quite poor prognosis. Currently, surgery for the primary tumor significantly prolonged the survival of those patients, whereas chemotherapy and radiotherapy need to be further confirmed.

Deciphering the Prognostic and Therapeutic Significance of Cell Cycle Regulator CENPF: A Potential Biomarker of Prognosis and Immune Microenvironment for Patients with Liposarcoma

“…LPS is a type of soft tissue sarcoma that accounts for 20% of the mesenchymal malignancies [ 44 ] with a high prevalence in the neck, head, retroperitoneum and extremities [ 45 ]. The metastasis of LPS could affect the survival outcome of patients, which is a challenge to the surgical resection and the stable state maintained by chemotherapy [ 46 , 47 ]. In recent years, molecular targeted therapy has been becoming a promising treatment modality that contributes to improving the survival of LPS patients [ 48 ].…”

Evaluation of Efficacy of Adjuvant Radiotherapy in Well-Differentiated Liposarcoma Patients with Positive Surgical Margins: A Population-based Study

“…Previous studies on the multivariate analysis associated with CSS had shown different results. Wang et al found that age at diagnosis <60 was significantly correlated with improved CSS [ 15 ]. In addition, a study by Ye et al identified that age, sex, and tumor size were independent prognostic variables for CSS in extremity liposarcoma patients [ 16 ].…”